ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

419
Analysis
Health CareChina
WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions.
more
Refresh
29 Jun 2020 23:52

Global Equity Chart Book: Stick With EM Over EAFE

With RS uptrends intact we continue to recommend Sector overweights to MSCI EM Technology, Consumer Discretionary, Health Care, and Communications....

Logo
400 Views
Share
bullishWuxi Biologics
29 Jun 2020 18:42

Wuxi Biologics Placement - This Time It's Different

Wuxi Biologics (Cayman) Inc (2269 HK) is looking to raise around US$660m in a primary placement. This is in contrast to the nine other placement...

Logo
448 Views
Share
bullishNetEase Inc
24 May 2020 14:20

ECM Weekly (24 May 2020) - NetEase and JD Homecoming, Legend Biotech, Nongfu Spring, Yeahka

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. The talk...

Share
bullishWuxi Biologics
20 May 2020 18:24

Wuxi Biologics Placement - Biggest Deal Size at Launch, Well Ahead of Lock-Up Expiry

Wuxi Biologics Holdings is looking to raise up to US$826m by selling 3.8% of Wuxi Biologics (Cayman) Inc (2269 HK). This will be ninth placement by...

Share
13 May 2020 07:56

China Health Care - Allocation Boom: Wuxi Biologics/Jinyu Bio-Tech/Hangzhou Tigermed Top Picks

With increased focus on the Health Care sector in light of the COVID-19 pandemic, Health Care allocations reached record levels last month. We...

Logo
303 Views
Share
x